PB0011 - Von Willebrand factor levels at 3 months after endothelial injury in Acute Coronary Syndrome: Single center experience.

Sunday, July 10, 2022

6:30 PM – 7:30 PM

Location: Exhibition

Presentation Format: In-Person

Presenting Author(s)

Cristina García Herce, MD

Resident doctor
Hospital Universitario de La Princesa
SPAIN, Madrid, Spain

Co-Author(s)

Bv

Blanca vegas

Resident doctor
Hospital Universitario de La Princesa
Madrid, Madrid, Spain
SF

Samantha Feijóo

Resident doctor
Hospital Universitario de La Princesa
Madrid, Madrid, Spain
AA

Alejandro Alonso

Resident doctor
Hospital Universitario de La Princesa
Madrid, Madrid, Spain
BL

Beatriz López

Hematologist
Hospital Universitario de La Princesa
Madrid, Madrid, Spain
Pr

Pilar roquero

Resident doctor
Hospital Universitario de La Princesa
Madrid, Madrid, Spain
NA

Natalia Acedo

Hematologist
Hospital Universitario de La Princesa
Madrid, Madrid, Spain

Background: Von Willebrand factor (vWf) is a plasma protein that is synthesized in endothelial cells. In the acute moment of ischemic cardiovascular disease, high vWf levels are reported in the literature. There is less evidence of vWf elevation after 3 months.

Aims: To analyze the vWf levels in patients with Acute Coronary Syndrome (ACS) after 3 months of the event in our center.

Methods: We carried out a single-center prospective study, including consecutively 63 patients < 60 years admitted to Cardiology Unit with ACS between the years 2020 and 2021, in which we quantified vWf levels. The patients were divided into 2 groups according to vWf parameters: normal VWF levels (50%-150%) or elevated (>150%). All patients gave informed consent.

Results: Table I shows the demographical and clinical characteristics of patients. Median time from the event to the blood test was 3.6 (3.3-4.4) months.
vWf median plasma levels were normal in 26 out of 63 (41.3%) and increased in 37 patients (58.7%). 78.3% of patients with high levels of vWf had previous medical history of arterial ischemia. 51.4% of patients with high levels of vWf had ST-elevation myocardial infarction.
Multiple artery coronary affection was observed in 14 patients with normal vWf (53.9%) and in 24 patients with increased vWf levels (64.9%). Multiple coronary stenosis >50% was observed in 15 patients with normal vWf (57.7%) and in 24 patients with increased vWf levels (64.9%).

Conclusion(s): Our results show that patients with increased plasma VWF levels after 3 months of a cardiovascular event, have more previous medical history of arterial ischemia and higher endothelial injury than patients with normal levels. Further studies are needed to confirm these results.